Raisa Balbuena-Merle1, Susanna A Curtis2, Lesley Devine1, David R Gibb1, Matthew S Karafin3,4, Chance John Luckey5, Christopher A Tormey1,6, Alexa J Siddon1,6,7, John D Roberts2, Jeanne E Hendrickson1,8. 1. Department of Laboratory Medicine, Yale University, New Haven, Connecticut. 2. Division of Hematology/Oncology, Yale University, New Haven, Connecticut. 3. Medical Sciences Institute, Blood Center of Wisconsin, part of Versiti, Milwaukee, WI. 4. Department of Pathology, Medical College of Wisconsin, Milwaukee, WI. 5. Department of Pathology, University of Virginia, Charlottesville, Virginia. 6. VA Connecticut, Pathology and Laboratory Medicine Service, West Haven, Connecticut. 7. Department of Pathology, Yale University, New Haven, Connecticut. 8. Department of Pediatrics, Yale University, New Haven, Connecticut.
Abstract
BACKGROUND: Despite the clinical significance of red blood cell (RBC) alloantibodies, there are currently no laboratory tests available to predict which patients may be at risk of antibody formation after transfusion exposure. Given their phagocytic and inflammatory functions, we hypothesized that differences in circulating monocytes may play a role in alloimmunization. STUDY DESIGN AND METHODS: Forty-two adults with sickle cell disease (SCD) were recruited, with data extracted from the electronic medical record and peripheral blood analyzed by flow cytometry for total monocytes, monocyte subsets (CD14 high/CD16 low+ classical monocytes, CD14 high/CD16 high+ intermediate monocytes, and CD14 intermediate/CD16 high+ non-classical/inflammatory monocytes), and FcγR1 (CD64) expression. Thirteen "non-responder" patients (non-alloimmunized patients with documented RBC transfusion at the study institution) were compared to 20 alloimmunized "responder" patients, who had a total of 44 RBC alloantibodies identified. RESULTS: There were no significant differences in the percentages of total monocytes, monocyte subsets, or measured cytokines between non-responders and responders. However, non-responders had higher CD64 expression on classical monocytes (MFI mean 3424 ± standard deviation 1141) compared to responders (MFI mean 2285 ± 1501), p = 0.029, and on intermediate monocytes (MFI mean 3720 ± 1191) compared to responders (MFI mean 2497 ± 1640), p = 0.033. CONCLUSIONS: Monocytes and the inflammatory milieu increasingly are being appreciated to play a role in some complications of SCD. The differences in FcγR1 expression on monocyte subsets noted between responders and non-responders, which cannot be directly explained by the serum cytokines evaluated, warrant further investigation.
BACKGROUND: Despite the clinical significance of red blood cell (RBC) alloantibodies, there are currently no laboratory tests available to predict which patients may be at risk of antibody formation after transfusion exposure. Given their phagocytic and inflammatory functions, we hypothesized that differences in circulating monocytes may play a role in alloimmunization. STUDY DESIGN AND METHODS: Forty-two adults with sickle cell disease (SCD) were recruited, with data extracted from the electronic medical record and peripheral blood analyzed by flow cytometry for total monocytes, monocyte subsets (CD14 high/CD16 low+ classical monocytes, CD14 high/CD16 high+ intermediate monocytes, and CD14 intermediate/CD16 high+ non-classical/inflammatory monocytes), and FcγR1 (CD64) expression. Thirteen "non-responder" patients (non-alloimmunized patients with documented RBC transfusion at the study institution) were compared to 20 alloimmunized "responder" patients, who had a total of 44 RBC alloantibodies identified. RESULTS: There were no significant differences in the percentages of total monocytes, monocyte subsets, or measured cytokines between non-responders and responders. However, non-responders had higher CD64 expression on classical monocytes (MFI mean 3424 ± standard deviation 1141) compared to responders (MFI mean 2285 ± 1501), p = 0.029, and on intermediate monocytes (MFI mean 3720 ± 1191) compared to responders (MFI mean 2497 ± 1640), p = 0.033. CONCLUSIONS: Monocytes and the inflammatory milieu increasingly are being appreciated to play a role in some complications of SCD. The differences in FcγR1 expression on monocyte subsets noted between responders and non-responders, which cannot be directly explained by the serum cytokines evaluated, warrant further investigation.
Authors: David R Gibb; Jingchun Liu; Prabitha Natarajan; Manjula Santhanakrishnan; David J Madrid; Stephanie C Eisenbarth; James C Zimring; Akiko Iwasaki; Jeanne E Hendrickson Journal: J Immunol Date: 2017-06-19 Impact factor: 5.422
Authors: B N Yamaja Setty; Nigel S Key; A Koneti Rao; Suhita Gayen-Betal; Suba Krishnan; Carlton D Dampier; Marie J Stuart Journal: Br J Haematol Date: 2012-02-24 Impact factor: 6.998
Authors: David R Gibb; Jingchun Liu; Manjula Santhanakrishnan; Prabitha Natarajan; David J Madrid; Seema Patel; Stephanie C Eisenbarth; Christopher A Tormey; Sean R Stowell; Akiko Iwasaki; Jeanne E Hendrickson Journal: Transfusion Date: 2017-08-23 Impact factor: 3.157
Authors: Stella T Chou; Tannoa Jackson; Sunitha Vege; Kim Smith-Whitley; David F Friedman; Connie M Westhoff Journal: Blood Date: 2013-05-30 Impact factor: 22.113
Authors: Anna Solovey; Arif Somani; John D Belcher; Liming Milbauer; Lucile Vincent; Rafal Pawlinski; Karl A Nath; Robert J Kelm; Nigel Mackman; M Gerard O'Sullivan; Kalpna Gupta; Gregory M Vercellotti; Robert P Hebbel Journal: Am J Hematol Date: 2017-07-29 Impact factor: 10.047